Pinnacle Associates Ltd. lowered its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 4.5% during the fourth quarter, Holdings Channel reports. The firm owned 14,179 shares of the biotechnology company’s stock after selling 670 shares during the period. Pinnacle Associates Ltd.’s holdings in United Therapeutics Corporation were worth $2,034,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Scopia Capital Management LP bought a new position in United Therapeutics Corporation during the third quarter worth approximately $483,266,000. Russell Investments Group Ltd. bought a new position in United Therapeutics Corporation during the fourth quarter worth approximately $61,510,000. Consonance Capital Management LP increased its position in United Therapeutics Corporation by 95.5% in the third quarter. Consonance Capital Management LP now owns 818,700 shares of the biotechnology company’s stock worth $96,672,000 after buying an additional 400,000 shares during the period. AQR Capital Management LLC increased its position in United Therapeutics Corporation by 21.2% in the second quarter. AQR Capital Management LLC now owns 1,584,113 shares of the biotechnology company’s stock worth $167,790,000 after buying an additional 277,266 shares during the period. Finally, First Trust Advisors LP increased its position in United Therapeutics Corporation by 92.8% in the third quarter. First Trust Advisors LP now owns 480,971 shares of the biotechnology company’s stock worth $56,793,000 after buying an additional 231,502 shares during the period.

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded down 0.306% during mid-day trading on Friday, hitting $167.905. 163,739 shares of the company’s stock were exchanged. The company has a market capitalization of $7.12 billion, a price-to-earnings ratio of 11.363 and a beta of 1.42. United Therapeutics Corporation has a 52 week low of $97.52 and a 52 week high of $168.82. The firm has a 50 day moving average price of $156.15 and a 200-day moving average price of $133.21.

This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this report can be accessed at http://www.watchlistnews.com/united-therapeutics-corporation-uthr-shares-sold-by-pinnacle-associates-ltd/1122616.html.

UTHR has been the topic of a number of research analyst reports. Barclays PLC downgraded shares of United Therapeutics Corporation from an “equal weight” rating to an “underweight” rating and reduced their price objective for the company from $115.00 to $100.00 in a research note on Tuesday, November 29th. Oppenheimer Holdings, Inc. initiated coverage on shares of United Therapeutics Corporation in a research note on Wednesday, December 14th. They set an “outperform” rating and a $160.00 price objective on the stock. Zacks Investment Research downgraded shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, October 20th. Wedbush reiterated an “outperform” rating and set a $229.00 price objective on shares of United Therapeutics Corporation in a research note on Friday, November 4th. Finally, Ladenburg Thalmann Financial Services upgraded shares of United Therapeutics Corporation from a “neutral” rating to a “buy” rating and increased their price objective for the company from $128.00 to $138.00 in a research note on Friday, October 28th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the stock. United Therapeutics Corporation has an average rating of “Hold” and an average price target of $136.42.

In other news, CEO Martine A. Rothblatt sold 1,214 shares of United Therapeutics Corporation stock in a transaction that occurred on Thursday, January 12th. The shares were sold at an average price of $142.37, for a total value of $172,837.18. Following the transaction, the chief executive officer now owns 1,354 shares of the company’s stock, valued at $192,768.98. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Christopher Patusky sold 5,000 shares of United Therapeutics Corporation stock in a transaction that occurred on Thursday, January 12th. The shares were sold at an average price of $141.99, for a total transaction of $709,950.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $709,950. The disclosure for this sale can be found here. In the last three months, insiders sold 19,778 shares of company stock worth $2,728,567. Insiders own 7.50% of the company’s stock.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.